Skip to main content
. 2022 Oct 19;44(1):121–137. doi: 10.1093/epirev/mxac010

Table 1.

Demographics for the STAR*D Trial at Level 2, Among Patients Randomized to Receive Venlafaxine, Bupropion, or Sertraline

Bupropion(n = 223) Sertraline (n = 215) Venlafaxine (n = 223)
Variable No. % No. % No. %
Age, yearsa 42.3 (13.0) 43.3 (12.7) 41.5 (12.5)
QIDS-SR at level entrya 13 (5.03) 13.20 (4.73) 13.33 (5.06)
QIDS-CR at level entrya 14 (4.55) 13.93 (4.37) 14.09 (4.63)
Male sex 96 43.0 98 45.6 85 38.1
On medical or psychaitric leave 21 9.4 16 7.4 21 9.4
Receiving public aid 17 7.6 11 5.1 15 6.7
Receiving Medicaid 39 17.6 23 10.7 22 9.9
Has private health insurance 99 44.4 88 40.9 102 45.7
Family and friends helpful 108 48.4 81 37.7 84 37.7
Married 72 32.3 70 32.6 75 33.6
Lives alone 60 26.9 55 25.6 49 22.0
Completed high school 115 51.6 122 56.7 121 54.3
Student 25 11.2 24 11.2 36 16.1
Working for pay 123 55.2 106 49.3 125 56.1
Volunteering 25 11.2 32 14.9 35 15.7
Able to make important decisions 104 46.6 98 45.6 97 43.5
Able to enjoy things 202 90.6 198 92.1 197 88.3
No. of assessments per patienta 3.3 (1.4) 3.4 (1.4) 3.5 (1.4)
Gaps between visits, daysa 17 (7) 17 (7) 18 (8)
Time of last visit, daysb 49 (33, 63) 49 (40, 63) 57 (37, 63)

Abbreviations: QIDS-CR, Quick Inventory of Depressive Symptomology, clinician-rated; QIDS-SR, Quick Inventory of Depressive Symptomology, self-reported.

a Values are expressed as mean (standard deviation).

b Values are expressed as median (interquartile range).